For the second year running, Denmark’s biotech sector is awarded a global top three ranking by Scientific American Worldview and is praised for its generous public sector investment and speedy drug trial application process.

Denmark takes the global top three spot in the 2016 Scientific American Worldview Scorecard, assessing countries worldwide according to their biotechnology innovation potential, ahead of its European contemporaries.

Denmark gets the top score for intensity, boasting 215.4 international patent applications filed per million inhabitants. When compared to Europe’s four largest economies, Denmark’s productive patent filing puts the country ahead of the UK, France and the Netherlands, second only to Germany.

Exports for 17 billion Euros per year
Denmark’s life sciences sector employs more than 40,000 people, primarily in Greater Copenhagen. Many of these highly skilled employees are located in Medicon Valley, home to almost 400 biotech and medtech companies. Add to this generous public sector investment of around 5.6 billion Euros as well as a drug trial application process of approx. 6 weeks and a high approval rate of approx. 95%.

It is hardly surprising that medical products account for Denmark’s largest export category estimated to be worth approximately 17 billion Euros per year.
Read the full report results: www.saworldview.com

Source: www.copcap.com
Photo: absfreepic.com